Captor Therapeutics SA

Captor Therapeutics SA

11.88
EUR
-0.18
(-1.49%)
-1.82EPS
113.11MMarket Cap
Dec 02Next Earn

Total Valuation

EUR

As of June 30, 2026, Captor Therapeutics SA carries a market capitalization of 113.11M, placing it among publicly traded companies globally. Its enterprise value stands at 97.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap113.11M
Enterprise Value97.09M

Important Dates

Captor Therapeutics SA's next confirmed earnings release is scheduled for December 2, 2026.

Earnings Date12/2/2026

Share Statistics

As of June 30, 2026, Captor Therapeutics SA has 6.33M shares outstanding.

Shares Outstanding6.33M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 218.82, and the price-to-book ratio stands at 7.47.

PS Ratio218.82
PB Ratio7.47
P/TBV Ratio7.58
P/FCF Ratio-5.85
P/OCF Ratio-5.90

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 207.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 97.09M versus a market cap of 113.11M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales207.93

Financial Position

As of June 30, 2026, Captor Therapeutics SA maintains a current ratio of 5.41, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.09, indicating elevated leverage, while an interest coverage ratio of -164.78 demonstrates limited ability to service its debt obligations.

Current Ratio5.41
Quick Ratio5.17
Debt / Equity4.09
Debt / EBITDA-0.06
Interest Coverage-164.78

Financial Efficiency

EUR

Over the twelve months ended June 30, 2026, Captor Therapeutics SA posted a negative return on equity (ROE) of -80.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -65.80, reflecting losses generated across the asset base. The company generates approximately 4,206.73 in revenue per employee across its workforce of 111.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-80.62
Return on Assets (ROA)-65.80
Revenue Per Employee4,206.73
Employee Count111.00

Taxes

EUR

Over the twelve months ended June 30, 2026, Captor Therapeutics SA recorded 6,284.93 in income tax expense. The company reported a pretax loss of -10.30M and -10.31M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax6,284.93

Stock Price Statistics

EUR

As of the close on November 17, 2026, Captor Therapeutics SA's stock has gained approximately 8.00% over the past 52 weeks. The 50-day moving average sits at 14.12, while the 200-day moving average is 17.08.

52-Week Price Change8.00%
50-Day Moving Average14.12
200-Day Moving Average17.08

Income Statement

EUR

Over the twelve months ended June 30, 2026, Captor Therapeutics SA generated 466,947.09 in revenue and converted that into -10.31M in net income, yielding earnings per share of -1.82. EBITDA reached -9.93M, while operating income came in at -10.79M.

Revenue466,947.09
Gross Profit897,115.69
Operating Income-10.79M
Pretax Income-10.30M
Net Income-10.31M
EBITDA-9.93M
EBIT-10.77M
Earnings Per Share (EPS)-1.82

Balance Sheet

EUR

As of June 30, 2026, Captor Therapeutics SA holds 16.64M in cash and equivalents against 619,182.08 in total debt, resulting in a net debt position of -559,358.85. Total book value stands at 15.15M, with working capital of 14.19M providing operational flexibility.

Cash & Cash Equivalents16.64M
Total Debt619,182.08
Net Debt-559,358.85
Equity (Book Value)15.15M
Book Value Per Share2.39
Working Capital14.19M

Cash Flow

EUR

Captor Therapeutics SA produced -17.32M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-17.32M
Free Cash Flow-17.32M
FCF Per Share-3.03

Margins

Over the twelve months ended June 30, 2026, Captor Therapeutics SA posted a gross margin of 192.12, reflecting its pricing power and cost economics. The operating margin of -2,311.12 and net profit margin of -2,207.63 provide insight into operational efficiency.

Gross Margin192.12
Operating Margin-2,311.12
Pretax Margin-2,206.28
Profit Margin-2,207.63
EBITDA Margin-2,127.52

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.29, meaning Captor Therapeutics SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-19.29
FCF Yield-17.10

Scores

As of June 30, 2026, Captor Therapeutics SA has an Altman Z-Score of 14.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score14.38